IN8bio Shares Pop 32% on Early Cancer Treatment Data

Dow Jones04-10

By Ben Glickman

Shares of IN8bio rose in late trading after the company said early data on its potential cancer treatment suggested it may be able to avoid killing healthy cells.

The stock was up 32% to $1.44 in post-market trading Tuesday after closing the day's session unchanged. Shares are down 21% since the start of the year.

The biopharmaceutical company said it had presented preclinical data on its potential cancer treatment at a conference. The T cell-based Chimeric Antigen Receptor-T cell platform, which the company refers to as INB-300, showed an improved ability to target leukemia cells while leaving healthy ones alone, the company said.

IN8bio said its platform was based on the ability of certain T cells to distinguish between healthy and cancerous cells. The company believes its technology will allow for a more targeted T-cell cancer treatment.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

April 09, 2024 19:09 ET (23:09 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426755791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-10 07:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426755791","market":"fut","top_or_hot":-1,"title":"IN8bio Shares Pop 32% on Early Cancer Treatment Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of IN8bio rose in late trading after the company said early data on its potential cancer treatment suggested it may be able to avoid killing healthy cells. \n</p>\n<p>\n  The stock was up 32% to $1.44 in post-market trading Tuesday after closing the day's session unchanged. Shares are down 21% since the start of the year. \n</p>\n<p>\n  The biopharmaceutical company said it had presented preclinical data on its potential cancer treatment at a conference. The T cell-based Chimeric Antigen Receptor-T cell platform, which the company refers to as INB-300, showed an improved ability to target leukemia cells while leaving healthy ones alone, the company said. \n</p>\n<p>\n  IN8bio said its platform was based on the ability of certain T cells to distinguish between healthy and cancerous cells. The company believes its technology will allow for a more targeted T-cell cancer treatment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 09, 2024 19:09 ET (23:09 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8bio Shares Pop 32% on Early Cancer Treatment Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8bio Shares Pop 32% on Early Cancer Treatment Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 07:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Shares of IN8bio rose in late trading after the company said early data on its potential cancer treatment suggested it may be able to avoid killing healthy cells. \n\n\n  The ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2426755791","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426755791","pubTimestamp":1712704140,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of IN8bio rose in late trading after the company said early data on its potential cancer treatment suggested it may be able to avoid killing healthy cells.The stock was up 32% to $1.44 in post-market trading Tuesday after closing the day's session unchanged. Shares are down 21% since the start of the year.The biopharmaceutical company said it had presented preclinical data on its potential cancer treatment at a conference. The T cell-based Chimeric Antigen Receptor-T cell platform, which the company refers to as INB-300, showed an improved ability to target leukemia cells while leaving healthy ones alone, the company said.IN8bio said its platform was based on the ability of certain T cells to distinguish between healthy and cancerous cells. The company believes its technology will allow for a more targeted T-cell cancer treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","INAB":"IN8bio, Inc.","BK4139":"生物科技"},"translate_title":"IN8bio股价因早期癌症治疗数据上涨32%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":1},"content_text":"By Ben Glickman \n\n\n \n\n\n  Shares of IN8bio rose in late trading after the company said early data on its potential cancer treatment suggested it may be able to avoid killing healthy cells. \n\n\n  The stock was up 32% to $1.44 in post-market trading Tuesday after closing the day's session unchanged. Shares are down 21% since the start of the year. \n\n\n  The biopharmaceutical company said it had presented preclinical data on its potential cancer treatment at a conference. The T cell-based Chimeric Antigen Receptor-T cell platform, which the company refers to as INB-300, showed an improved ability to target leukemia cells while leaving healthy ones alone, the company said. \n\n\n  IN8bio said its platform was based on the ability of certain T cells to distinguish between healthy and cancerous cells. The company believes its technology will allow for a more targeted T-cell cancer treatment. \n\n\n \n\n\n  Write to Ben Glickman at ben.glickman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2024 19:09 ET (23:09 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426755791"}